XGN Valuation

Exagen Inc

Add to Watchlist

Advanced Chart

9.560

-0.82(-7.900%)1D

XGN Relative Valuation

XGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XGN is overvalued; if below, it's undervalued.

Historical Valuation

Exagen Inc (XGN) is now in the Overvalued zone, suggesting that its current forward PS ratio of 9.56 is considered Overvalued compared with the five-year average of -5.26. The fair price of Exagen Inc (XGN) is between 4.55 to 7.24 according to relative valuation methord. Compared to the current price of 9.56 USD , Exagen Inc is Overvalued By 32.01%.

Relative Value

Fair Zone

4.55-7.24

Current Price：9.56

32.01%

Overvalued

-18.38

Trailing

Forward

-104.67

EV/EBITDA

Exagen Inc. (XGN) has a current EV/EBITDA of -104.67. The 5-year average EV/EBITDA is -10.51. The thresholds are as follows: Strongly Undervalued below -55.55, Undervalued between -55.55 and -33.03, Fairly Valued between 12.01 and -33.03, Overvalued between 12.01 and 34.54, and Strongly Overvalued above 34.54. The current Forward EV/EBITDA of -104.67 falls within the Strongly Undervalued range.

-26.06

EV/EBIT

Exagen Inc. (XGN) has a current EV/EBIT of -26.06. The 5-year average EV/EBIT is -4.83. The thresholds are as follows: Strongly Undervalued below -18.25, Undervalued between -18.25 and -11.54, Fairly Valued between 1.88 and -11.54, Overvalued between 1.88 and 8.59, and Strongly Overvalued above 8.59. The current Forward EV/EBIT of -26.06 falls within the Strongly Undervalued range.

9.56

Exagen Inc. (XGN) has a current PS of 9.56. The 5-year average PS is 2.12. The thresholds are as follows: Strongly Undervalued below -1.24, Undervalued between -1.24 and 0.44, Fairly Valued between 3.80 and 0.44, Overvalued between 3.80 and 5.48, and Strongly Overvalued above 5.48. The current Forward PS of 9.56 falls within the Strongly Overvalued range.

826.54

P/OCF

Exagen Inc. (XGN) has a current P/OCF of 826.54. The 5-year average P/OCF is -7.28. The thresholds are as follows: Strongly Undervalued below -82.27, Undervalued between -82.27 and -44.78, Fairly Valued between 30.22 and -44.78, Overvalued between 30.22 and 67.71, and Strongly Overvalued above 67.71. The current Forward P/OCF of 826.54 falls within the Strongly Overvalued range.

284.12

P/FCF

Exagen Inc. (XGN) has a current P/FCF of 284.12. The 5-year average P/FCF is -8.26. The thresholds are as follows: Strongly Undervalued below -47.85, Undervalued between -47.85 and -28.06, Fairly Valued between 11.54 and -28.06, Overvalued between 11.54 and 31.33, and Strongly Overvalued above 31.33. The current Forward P/FCF of 284.12 falls within the Strongly Overvalued range.

Exagen Inc (XGN) has a current Price-to-Book (P/B) ratio of 11.86. Compared to its 3-year average P/B ratio of 4.40 , the current P/B ratio is approximately 169.38% higher. Relative to its 5-year average P/B ratio of 3.59, the current P/B ratio is about 230.23% higher. Exagen Inc (XGN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -46.28%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -35.95% , the current FCF yield is about -100.00% lower.

11.86

P/B

Median3y

4.40

Median5y

3.59

0.00

FCF Yield

Median3y

-46.28

Median5y

-35.95

Competitors Valuation Multiple

The average P/S ratio for XGN's competitors is 18.27, providing a benchmark for relative valuation. Exagen Inc Corp (XGN) exhibits a P/S ratio of 9.56, which is -47.68% above the industry average. Given its robust revenue growth of 37.87%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Burning Rock Biotech Ltd

Performance Decomposition

Market capitalization of XGN increased by 140.81% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -5.07 to -10.18.

The secondary factor is the Revenue Growth, contributed 37.87%to the performance.

Overall, the performance of XGN in the past 1 year is driven by P/E Change. Which is more unsustainable.

37.87%

12.51M → 17.24M

Revenue Growth

2.24%

-40.20 → -41.10

Margin Expansion

100.70%

-5.07 → -10.18

P/E Change

140.81%